160098-96-4 | 4-(furan-2-yl)-10-(2-phenylethyl)-3,5,6,8,10,11-hexaazatricyclo[7.3.0.0^{2,6}]dodeca-1(9),2,4,7,11-pentaen-7-amine

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$18.00	$13.00
5mg	98%	in stock	$52.00	$36.00
10mg	98%	in stock	$66.00	$46.00
50mg	98%	in stock	$160.00	$112.00
100mg	98%	in stock	$273.00	$191.00
250mg	98%	in stock	$464.00	$325.00
1g	98%	in stock	$1,251.00	$876.00

Description

• Catalog Number: AA82293
• Chemical Name: 4-(furan-2-yl)-10-(2-phenylethyl)-3,5,6,8,10,11-hexaazatricyclo[7.3.0.0^{2,6}]dodeca-1(9),2,4,7,11-pentaen-7-amine
• CAS Number: 160098-96-4
• Molecular Formula: C18H15N7O
• Molecular Weight: 345.358
• MDL Number: MFCD00933778
• SMILES: Nc1nc2n(CCc3ccccc3)ncc2c2n1nc(n2)c1ccco1

Computed Properties

• Complexity: 488
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 2.4

Literature

• Adenosine A2A and A2B Receptor Substantially Attenuate Ischemia/Reperfusion Injury in Septic rat Hearts.

  Cardiovascular drugs and therapy 20160101

• Adenosine A2A receptor as a drug discovery target.

  Journal of medicinal chemistry 20140508

• Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells.

  Journal of immunology (Baltimore, Md. : 1950) 20131215

• Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγ.

  American journal of physiology. Regulatory, integrative and comparative physiology 20130101

• Adenosine A2a receptor induces GDNF expression by the Stat3 signal in vitro.

  Neuroreport 20121114

• Selective blockade of A(2A) receptor protects against neurotoxicity induced by kainic acid in young rats.

  Fundamental & clinical pharmacology 20120801

• Characterization of the Drosophila adenosine receptor: the effect of adenosine analogs on cAMP signaling in Drosophila cells and their utility for in vivo experiments.

  Journal of neurochemistry 20120501

• SCH58261 the selective adenosine A(2A) receptor blocker modulates ischemia reperfusion injury following bilateral carotid occlusion: role of inflammatory mediators.

  Neurochemical research 20120301

• Distinctive immunoregulatory effects of adenosine on T cells of older humans.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20120301

• Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.

  Bioorganic & medicinal chemistry 20120115

• A novel fused 1,2,4-triazine aryl derivative as antioxidant and nonselective antagonist of adenosine A(2A) receptors in ethanol-activated liver stellate cells.

  Chemico-biological interactions 20120105

• Enhanced IL-6 transcriptional response to adenosine receptor ligands in horses with lower airway inflammation.

  Equine veterinary journal 20120101

• Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion.

  Neurobiology of disease 20120101

• Combined contribution of endothelial relaxing autacoides in the rat femoral artery response to CPCA: an adenosine A2 receptor agonist.

  TheScientificWorldJournal 20120101

• Astrocytic adenosine A2A receptors control the amyloid-β peptide-induced decrease of glutamate uptake.

  Journal of Alzheimer's disease : JAD 20120101

• Blockade of adenosine A2A receptors prevents interleukin-1β-induced exacerbation of neuronal toxicity through a p38 mitogen-activated protein kinase pathway.

  Journal of neuroinflammation 20120101

• Adenosine reduces cell surface expression of toll-like receptor 4 and inflammation in response to lipopolysaccharide and matrix products.

  Journal of cardiovascular translational research 20111201

• Differential neuroprotection by A(1) receptor activation and A(2A) receptor inhibition following pilocarpine-induced status epilepticus.

  Epilepsy & behavior : E&B 20111001

• [Protective effect of new adenosine analog B2 against serum deprivation-induced PC12 cell injury].

  Yao xue xue bao = Acta pharmaceutica Sinica 20111001

• Enhanced role of adenosine A(2A) receptors in the modulation of LTP in the rat hippocampus upon ageing.

  The European journal of neuroscience 20110701

• Adenosine A2A receptor induces protein kinase A-dependent functional modulation of human (alpha)3(beta)4 nicotinic receptor.

  The Journal of physiology 20110601

• [Sedative, hypnotic and anticonvulsive effects of an adenosine analogue WS090501].

  Yao xue xue bao = Acta pharmaceutica Sinica 20110601

• Protective effect of caffeine and a selective A2A receptor antagonist on impairment of memory and oxidative stress of aged rats.

  Experimental gerontology 20110401

• Novel 8-(furan-2-yl)-3-benzyl thiazolo [5,4-e][1,2,4] triazolo [1,5-c] pyrimidine-2(3H)-thione as selective adenosine A(2A) receptor antagonist.

  Neuroscience letters 20110113

• Involvement of adenosine signaling in controlling the release of ghrelin from the mouse stomach.

  The Journal of pharmacology and experimental therapeutics 20110101

• Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects.

  Journal of neuroinflammation 20110101

• Caffeine acts via A1 adenosine receptors to disrupt embryonic cardiac function.

  PloS one 20110101

• Inactivation of adenosine A2A receptor attenuates basal and angiotensin II-induced ROS production by Nox2 in endothelial cells.

  The Journal of biological chemistry 20101217

• Contribution of adenosine A(2A) and A(2B) receptors to ischemic coronary dilation: role of K(V) and K(ATP) channels.

  Microcirculation (New York, N.Y. : 1994) 20101101

• Afferent arteriolar vasodilator effect of adenosine predominantly involves adenosine A2B receptor activation.

  American journal of physiology. Renal physiology 20100801

• Ecto-5'-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation.

  Journal of immunology (Baltimore, Md. : 1950) 20100715

• Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.

  Cellular and molecular neurobiology 20100401

• Novel 8-(furan-2-yl)-3-substituted thiazolo [5,4-e][1,2,4] triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A(2A) receptor antagonists.

  Bioorganic & medicinal chemistry 20100401

• Glutamate-induced depression of EPSP-spike coupling in rat hippocampal CA1 neurons and modulation by adenosine receptors.

  The European journal of neuroscience 20100401

• CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.

  Cancer research 20100315

• A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.

  Neuropharmacology 20100301

• Adenosine up-regulates vascular endothelial growth factor in human macrophages.

  Biochemical and biophysical research communications 20100212

• Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX.

  Pharmacology, biochemistry, and behavior 20100201

• The stimulatory effects of caffeine with oseltamivir (Tamiflu) on light-dark behavior and open-field behavior in mice.

  Neuroscience letters 20100122

• Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.

  Neurobiology of disease 20100101

• Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life.

  Journal of neurochemistry 20100101

• Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice.

  Journal of biomedical science 20100101

• Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.

  Journal of neurochemistry 20091201

• Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20091125

• Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.

  Journal of immunology (Baltimore, Md. : 1950) 20091115

• Differential effects of adenosine antagonists in two models of parkinsonian tremor.

  Pharmacology, biochemistry, and behavior 20091101

• Adenosine A2a receptor induced gliosis via Akt/NF-kappaB pathway in vitro.

  Neuroscience research 20091101

• Absence of adenosine-mediated aortic relaxation in A(2A) adenosine receptor knockout mice.

  American journal of physiology. Heart and circulatory physiology 20091101

• Pharmacological modifications of the stretch-induced effects on ventricular fibrillation in perfused rabbit hearts.

  American journal of physiology. Heart and circulatory physiology 20091101

• Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease.

  The European journal of neuroscience 20090901

• Adenosine receptor antagonists and behavioral activation in NF-kappaB p50 subunit knockout mice.

  Life sciences 20090731

• Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.

  Bioorganic & medicinal chemistry 20090715

• Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression.

  The Journal of pharmacology and experimental therapeutics 20090701

• The adenosine A2A receptor antagonist ZM241385 enhances neuronal survival after oxygen-glucose deprivation in rat CA1 hippocampal slices.

  British journal of pharmacology 20090701

• Caffeine and a selective adenosine A2A receptor antagonist induce reward and sensitization behavior associated with increased phospho-Thr75-DARPP-32 in mice.

  Psychopharmacology 20090601

• Adenosine A(2A) receptor modulation of hippocampal CA3-CA1 synapse plasticity during associative learning in behaving mice.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090601

• Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia.

  Brain : a journal of neurology 20090601

• Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease.

  Pharmacology, biochemistry, and behavior 20090501

• Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors.

  British journal of pharmacology 20090101

• An adenosine A(2A) antagonist injected in the NTS reverses thermal prolongation of the LCR in decerebrate piglets.

  Respiratory physiology & neurobiology 20081231

• Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice.

  American journal of physiology. Heart and circulatory physiology 20081101

• Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice.

  Experimental neurology 20080901

• 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.

  Journal of medicinal chemistry 20080814

• Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists.

  Bioorganic & medicinal chemistry letters 20080715

• Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.

  Bioorganic & medicinal chemistry letters 20080715

• Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080521

• Caffeine and a selective adenosine A(2B) receptor antagonist but not imidazoline receptor antagonists modulate antinociception induced by diphenyl diselenide in mice.

  Neuroscience letters 20080509

• CNGA2 channels mediate adenosine-induced Ca2+ influx in vascular endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20080501

• Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists.

  Synapse (New York, N.Y.) 20080501

• Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine.

  Neuropharmacology 20080501

• Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801.

  Experimental neurology 20080401

• Combined antagonism of glutamate mGlu5 and adenosine A2A receptors interact to regulate alcohol-seeking in rats.

  The international journal of neuropsychopharmacology 20080301

• Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses.

  Neuron 20080110

• Brainstem phosphorylated extracellular signal-regulated kinase 1/2-nitric-oxide synthase signaling mediates the adenosine A2A-dependent hypotensive action of clonidine in conscious aortic barodenervated rats.

  The Journal of pharmacology and experimental therapeutics 20080101

• Effect of the pyridoindole SMe1EC2 and compounds affecting A(1) and A(2A) adenosine receptors in rat hippocampus under ischemia in vitro.

  Pharmacological reports : PR 20080101

• Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.

  Neurobiology of disease 20071101

• Transient inhibition of astrocytogenesis in developing mouse brain following postnatal caffeine exposure.

  Pediatric research 20071101

• Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus.

  Neuroscience 20071012

• Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.

  Synapse (New York, N.Y.) 20070801

• Determination of adenosine effects and adenosine receptors in murine corpus cavernosum.

  The Journal of pharmacology and experimental therapeutics 20070801

• A2A adenosine-receptor-mediated facilitation of noradrenaline release in rat tail artery involves protein kinase C activation and betagamma subunits formed after alpha2-adrenoceptor activation.

  Neurochemistry international 20070701

• Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration.

  Journal of neuropathology and experimental neurology 20070501

• Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.

  Naunyn-Schmiedeberg's archives of pharmacology 20070401

• 3H-[1,2,4]-Triazolo[5,1-i]purin-5-amine derivatives as adenosine A2A antagonists.

  Bioorganic & medicinal chemistry letters 20070315

• Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.

  Bioorganic & medicinal chemistry letters 20070301

• Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.

  Journal of pharmacological sciences 20070301

• Tonic adenosine A1 and A2A receptor activation is required for the excitatory action of VIP on synaptic transmission in the CA1 area of the hippocampus.

  Neuropharmacology 20070201

• A novel mechanism of vasoregulation: ADP-induced relaxation of the porcine isolated coronary artery is mediated via adenosine release.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070201

• Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.

  Behavioural brain research 20070125

• Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice.

  Experimental neurology 20070101

• Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20061227

• Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease.

  Journal of the neurological sciences 20061025

• Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A2A receptor-dependent manner.

  Brain research 20061003

• Increased density and synapto-protective effect of adenosine A2A receptors upon sub-chronic restraint stress.

  Neuroscience 20060915

• Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.

  Synapse (New York, N.Y.) 20060901

• Evidence for both adenosine A1 and A2A receptors activating single vagal sensory C-fibres in guinea pig lungs.

  The Journal of physiology 20060901

• Central adenosine signaling plays a key role in centrally mediated hypotension in conscious aortic barodenervated rats.

  The Journal of pharmacology and experimental therapeutics 20060701

• Characterization of adenosine receptors in the human bladder carcinoma T24 cell line.

  European journal of pharmacology 20060424

• Adenosine receptors as therapeutic targets.

  Nature reviews. Drug discovery 20060301

• The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia.

  Brain research 20060216

• Modulation of paracetamol antinociception by caffeine and by selective adenosine A2 receptor antagonists in mice.

  European journal of pharmacology 20060215

• Combination of adenosine A1 and A2A receptor blocking agents induces caffeine-like locomotor stimulation in mice.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20060201

• Hypoxia-induced desensitization and internalization of adenosine A1 receptors in the rat hippocampus.

  Neuroscience 20060101

• Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.

  Bioorganic & medicinal chemistry letters 20051101

• Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum.

  Physiological genomics 20050921

• Involvement of p38-mitogen-activated protein kinase in adenosine receptor-mediated relaxation of coronary artery.

  American journal of physiology. Heart and circulatory physiology 20050601

• Adenosine A2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus.

  Journal of neurochemistry 20050501

• 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists.

  Bioorganic & medicinal chemistry letters 20050415

• Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

  Journal of medicinal chemistry 20050324

• Mediators of coronary reactive hyperaemia in isolated mouse heart.

  British journal of pharmacology 20050201

• Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum.

  Journal of neurochemistry 20050201

• Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.

  Bioorganic & medicinal chemistry letters 20050201

• A2B adenosine receptor activity is reduced in neutrophils from patients with systemic sclerosis.

  Arthritis research & therapy 20050101

• Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat.

  Neuroscience 20050101

• Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.

  Journal of medicinal chemistry 20041202

• Regulation of A2B adenosine receptor functioning by tumour necrosis factor a in human astroglial cells.

  Journal of neurochemistry 20041201

• Adenosine A1 receptor blockade mimics caffeine's attenuation of ethanol-induced motor incoordination.

  Basic & clinical pharmacology & toxicology 20041201

• Adenosine receptors involved in modulation of noradrenaline release in isolated rat tail artery.

  European journal of pharmacology 20041103

• Glutamate efflux from human cerebrocortical slices during ischemia: vesicular-like mode of glutamate release and sensitivity to A(2A) adenosine receptor blockade.

  Neuropharmacology 20041101

• Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.

  Bioorganic & medicinal chemistry letters 20041004

• Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.

  Bioorganic & medicinal chemistry letters 20041004

• Effect of free radicals on adenosine A(2A) and dopamine D2 receptors in the striatum of young adult and aged rats.

  Neurochemistry international 20041001

• Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.

  Neurobiology of disease 20041001

• Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions.

  Experimental neurology 20040901

• Facilitation of noradrenaline release by activation of adenosine A(2A) receptors triggers both phospholipase C and adenylate cyclase pathways in rat tail artery.

  Cardiovascular research 20040901

• Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

  Journal of medicinal chemistry 20040812

• Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.

  Parkinsonism & related disorders 20040701

• Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum.

  Journal of neuroscience research 20040701

• Comparison of inhibitory activity of isomeric triazolopyridine derivatives towards adenosine receptor subtypes or do similar structures reveal similar bioactivities?

  Bioorganic & medicinal chemistry letters 20040621

• Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives.

  Journal of medicinal chemistry 20040603

• Adenosine A 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors.

  Journal of neurochemistry 20040401

• Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice.

  British journal of pharmacology 20040301

• Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities.

  Neurology 20031209

• Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.

  Neurology 20031209

• A2A receptors in neuroprotection of dopaminergic neurons.

  Neurology 20031209

• Modulation of glutamate release and excitotoxicity by adenosine A2A receptors.

  Neurology 20031209

• Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.

  Neurology 20031209

• Adenosine A2A receptors and depression.

  Neurology 20031209

• Caffeine reduces hypnotic effects of alcohol through adenosine A2A receptor blockade.

  Neuropharmacology 20031201

• Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree.

  European journal of pharmacology 20031128

• Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes.

  Glia 20030801

• Interactive role of adenosine and dopamine in the opiate withdrawal syndrome.

  Naunyn-Schmiedeberg's archives of pharmacology 20030801

• Adenosine A(2A) antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington's disease.

  Brain research 20030725

• SCH 58261, a selective adenosine A2A receptor antagonist, decreases the haloperidol-enhanced proenkephalin mRNA expression in the rat striatum.

  Brain research 20030711

• Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.

  Journal of medicinal chemistry 20030327

• Adenosine promotes neuronal recovery from reactive oxygen species induced lesion in rat hippocampal slices.

  Neuroscience letters 20030320

• Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats.

  European journal of pharmacology 20030307

• Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells.

  Molecular pharmacology 20030201

• The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat.

  Brain research 20030110

• Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats.

  Polish journal of pharmacology 20030101

• Transducing system operated by adenosine A(2A) receptors to facilitate acetylcholine release in the rat hippocampus.

  European journal of pharmacology 20021101

• SCH 58261 differentially influences quinolinic acid-induced effects in striatal and in hippocampal slices.

  European journal of pharmacology 20020830

• Effects of A(1) and A(2A) adenosine receptor ligands in mouse acute models of pain.

  Neuroscience letters 20020816

• Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine.

  Nature 20020815

• Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20020801

• Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020801

• Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.

  Synapse (New York, N.Y.) 20020601

• Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes.

  British journal of pharmacology 20020601

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020301

• Diverse inhibitors of intracellular signalling act as adenosine receptor antagonists.

  Cellular signalling 20020201

• Anoxia redistributes adenosine A(2A) receptors in PC12 cells and increases receptor-mediated formation of cAMP.

  Naunyn-Schmiedeberg's archives of pharmacology 20020201

• Blockade of A(2A) adenosine receptors leads to c-fos inhibition in a rat model of brain ischemia.

  Pharmacological research 20020201

• 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility.

  Journal of medicinal chemistry 20020103

• Adenosine A(2A) and A(2B) receptor activation of erythropoietin production.

  American journal of physiology. Renal physiology 20011101

• Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.

  British journal of pharmacology 20011101

• In vivo labelling of the adenosine A2A receptor in mouse brain using the selective antagonist [3H]SCH 58261.

  The European journal of neuroscience 20011101

• Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease.

  Neurotoxicity research 20011101

• Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.

  British journal of pharmacology 20010901

• Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells.

  British journal of pharmacology 20010901

• SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.

  Synapse (New York, N.Y.) 20010801

• Production of leukotrienes in a model of focal cerebral ischaemia in the rat.

  British journal of pharmacology 20010801

• SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum.

  European journal of pharmacology 20010615

• Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010515

• Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.

  Synapse (New York, N.Y.) 20010301

• Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20010201

• Selective adenosine A2A receptor antagonists.

  Farmaco (Societa chimica italiana : 1989) 20010101

• Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine.

  Molecular pharmacology 20001201

• Anticonvulsant effect and neurotransmitter modulation of focal and systemic 2-chloroadenosine against the development of pilocarpine-induced seizures.

  Neuropharmacology 20000901

• Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.

  Biochemical pharmacology 19990101

• Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.

  Naunyn-Schmiedeberg's archives of pharmacology 19990101

• Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.

  British journal of pharmacology 19970501

• The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.

  The Journal of pharmacology and experimental therapeutics 19960201

• A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding.

  The Journal of biological chemistry 19940128